Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial

J. Bengtson, M. Adolphson, D. L. Brewer, D. Jacobs, J. L. Gard, L. Cahoon, M. Bloom, B. Kennelly, K. Porter, J. Kmonicek, F. M. Krainin, J. Shane, J. F. Marquis, S. A. Kearns, D. J. Moliterno, P. DeSantis, E. M. Ohman, C. Martz, D. L. Brown, M. BulleyS. Worley, J. Slovak, L. Hollywood, K. Knepper, K. Browne, M. Telatnik, M. Frey, T. Browning, W. French, S. Wang, N. S. Kleiman, L. Baysinger, A. Edwards, G. Barbeau, M. M. Lariviere, J. Hermiller, S. Diel, J. S. Wilson, A. Friedewald, A. N. Tenaglia, R. Bozeman, W. Roper, W. Grossman, K. Fletcher, R. Andersen, L. Hollywood, D. Spriggs, S. Wahl, J. D. Talley, M. Boyles, D. Almond, J. White, A. G. Adelman, V. Foulger, S. Webber, C. Kells, T. Fawcett, J. Butler, J. Scrivner, M. J. Miller, B. Owens, C. Corder, C. Clinton, J. Johnson, M. Myrna, K. Carr, J. Calarco, J. Glassman, A. Stein, D. Marsh, B. Penny, D. Small, D. Goodman, D. Walston, J. Butler, J. Scrivner, M. J. Koren, K. Teeter, M. Hudson

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Background: Adjunctive therapies that increase the incidence of normal reperfusion after thrombolysis for acure myocardial infarction (MI) could enhance clinical outcomes. Direct thrombin inhibitors may offer an advantage over standard adjunctive therapies. Methods: We randomized 336 patients with acute MI at 33 sites to receive 1 of 5 doses of efegatran sulfate, a direct thrombin inhibitor, or heparin for 72 to 96 hours, both with accelerated alteplase and aspirin. The primary end point was the incidence of thrombolytic failure (death, reinfarction, or TIMI grade 0-2 flow in the infarct artery from 90 minutes to discharge or 30 days, whichever occurred earlier). Results: Significantly more patients randomized to efegatran had evidence of heart failure at admission. The lowest-dose efegatran arm was terminated at 15 patients because of unacceptably increased thrombolytic failure. The primary end point occurred in 53.0% of patients treated with heparin, in 53.8% of patients treated with efegatran overall (P =. 90), and in 55.4% of patients given intermediate-dose efegatran (P =. 74). These findings were unaffected after adjustment was done for baseline differences. Most bleeding was minor; major bleeding and the use of blood transfusions did not differ significantly by treatment. Three patients in the high-dose efegatran group had intracranial hemorrhage, as did 1 patient in the heparin group. Continuous ST monitoring showed a shorter time to recovery for the efegatran group (median 107 minutes) compared with the heparin group (154 minutes; P =. 025). Conclusions: Efegatran sulfate appeared to offer no dear advantage over heparin as an adjunct to thrombolysis for acute myocardial infarction, although there may be a modest improvement in time to reperfusion.

Original languageEnglish (US)
Pages (from-to)95-105
Number of pages11
JournalAmerican Heart Journal
Issue number1
StatePublished - 2002

Bibliographical note

Funding Information:
Funded by grants from Centocor, Inc, Malvern, Pa, and Eli Lilly and Company, Indianapolis, Ind.


Dive into the research topics of 'Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial'. Together they form a unique fingerprint.

Cite this